Sarepta Therapeutics (SRPT +12.9%) continues to be on a tear following a 14.3% gain yesterday....

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT +12.9%) continues to be on a tear following a 14.3% gain yesterday. Talk has been swirling around the company's Eteplirsen treatment for Duchenne muscular dystrophy, including a report by a Missouri news station that a boy showed marked improvement using the drug in clinical trials. Options activity in the name has been active, with call volume leaping 700% over its daily average.